Abcellera Debt To Assets from 2010 to 2025

ABCL Stock  USD 3.17  0.06  1.86%   
Abcellera Biologics Debt To Assets yearly trend continues to be quite stable with very little volatility. Debt To Assets may rise above 0.11 this year. From the period between 2010 and 2025, Abcellera Biologics, Debt To Assets regression line of its data series had standard deviation of  0.07 and standard deviation of  0.07. View All Fundamentals
 
Debt To Assets  
First Reported
2010-12-31
Previous Quarter
0.0598
Current Value
0.11
Quarterly Volatility
0.07207967
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Abcellera Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abcellera Biologics' main balance sheet or income statement drivers, such as Net Interest Income of 51 M, Interest Income of 51 M or Depreciation And Amortization of 37.3 M, as well as many indicators such as Price To Sales Ratio of 47.44, Dividend Yield of 0.0 or PTB Ratio of 1.57. Abcellera financial statements analysis is a perfect complement when working with Abcellera Biologics Valuation or Volatility modules.
  
Check out the analysis of Abcellera Biologics Correlation against competitors.
For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.

Latest Abcellera Biologics' Debt To Assets Growth Pattern

Below is the plot of the Debt To Assets of Abcellera Biologics over the last few years. It is Abcellera Biologics' Debt To Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Abcellera Biologics' overall financial position and show how it may be relating to other accounts over time.
Debt To Assets10 Years Trend
Slightly volatile
   Debt To Assets   
       Timeline  

Abcellera Debt To Assets Regression Statistics

Arithmetic Mean0.13
Geometric Mean0.1
Coefficient Of Variation56.43
Mean Deviation0.06
Median0.16
Standard Deviation0.07
Sample Variance0.01
Range0.2873
R-Value(0.53)
Mean Square Error0
R-Squared0.29
Significance0.03
Slope(0.01)
Total Sum of Squares0.08

Abcellera Debt To Assets History

2025 0.11
2024 0.0598
2023 0.052
2022 0.0534
2021 0.0276
2020 0.006069
2019 0.29

About Abcellera Biologics Financial Statements

Abcellera Biologics investors utilize fundamental indicators, such as Debt To Assets, to predict how Abcellera Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Debt To Assets 0.06  0.11 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Abcellera Biologics is a strong investment it is important to analyze Abcellera Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Abcellera Biologics' future performance. For an informed investment choice regarding Abcellera Stock, refer to the following important reports:
Check out the analysis of Abcellera Biologics Correlation against competitors.
For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.459
Earnings Share
(0.61)
Revenue Per Share
0.112
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.13)
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.